Figure 1: COVID-19 cases in Alberta by day and case status. Probable cases include cases where the lab confirmation is pending. Cases are under investigation and numbers may fluctuate as cases are resolved. Data included up to end of day May 01, 2023.
Characteristics
Table 1. COVID-19 cases in Alberta by age group and gender
Gender
Female
Male
Unknown
All
Age
Count
Percent
Count
Percent
Count
Percent
Count
Percent
Under 1 year
2,496
0
2,980
0
2
0
5,478
1
1-4 years
10,510
2
11,433
2
7
0
21,950
3
5-9 years
15,050
2
16,802
3
4
0
31,856
5
10-19 years
34,843
6
34,911
6
37
0
69,791
11
20-29 years
56,522
9
47,425
8
62
0
104,009
16
30-39 years
65,302
10
54,002
9
28
0
119,332
19
40-49 years
54,204
9
45,162
7
16
0
99,382
16
50-59 years
38,399
6
33,993
5
11
0
72,403
11
60-69 years
23,065
4
22,935
4
7
0
46,007
7
70-79 years
13,008
2
13,085
2
2
0
26,095
4
80+ years
22,055
3
13,781
2
36
0
35,872
6
Unknown
1
0
1
0
0
0
2
0
All
335,455
53
296,510
47
212
0
632,177
100
Figure 2: COVID-19 cases in Alberta by age group. First and second panels display counts (7-day rolling average) and rate per 100,000 (7-day rolling average), respectively.
Vaccinations
Vaccine Effectiveness
Overview
A large body of evidence suggests that vaccines are safe and effective against COVID-19.
All viruses evolve over time through genetic variations. These changes can cause the emergence of new “variants” of the original virus and may have different properties than the original virus, such as increased transmissibility or the ability to cause more severe disease. Omicron, along with its sub-variants, is the currently circulating variant of concern (VOC) in Alberta.
Omicron has demonstrated increased transmissibility and capacity to evade the body’s immune response compared to previous versions of the virus. This occurs whether this immunity was generated by infection, vaccines, or both.
The protection that vaccines provide against severe disease continues to be strong even many months after immunization. Two doses of a COVID vaccine dramatically reduce the risk of hospitalization or death, and a third dose will offer even more protection. A booster dose is recommended at 5 months after the second dose, and at least 3 months following infection with COVID-19, to increase the level of protection against severe outcomes.
COVID vaccines are not always able to provide protection against infection by Omicron or one of its subvariants. Immunity against infection wanes over time, but can be boosted with an another dose of an mRNA vaccine.
A systematic review of the evidence published between December 2021 and April 2022 in The Lancet Infectious Diseases found that the VE of a primary series (for most people, this is two doses) against severe outcomes remained high and stable over time at over 80%. [1, 2] VE against infection by Omicron was lower than for previous variants and waned over time with most protection against infection lost by 4-6 months post second dose. However, boosting with a third dose increased the VE against infection with Omicron (to about 60%) and against severe outcomes (to 90%). [1, 2]
The figure on page 20 of this document helps to illustrate the results from the evidence, for both the primary series as well as for a booster dose.
Another evidence review, published by McMaster University on June 22, 2022, also examined the effectiveness of COVID-19 vaccines against the Omicron variant. It found that in general, people with a primary series continue to have a good level of protection against hospitalisation and death due to COVID-19 for 7 to 8 months after being vaccinated. A third (booster) dose increases this protection against COVID-19 related hospitalisations, with a very minimal degree of waning after several months. [3]
In addition to reviews that assess the VE of second and third doses, there is emerging evidence on the benefit of a fourth dose. A recently published study in healthcare workers from Israel found that only 7% of those with a fourth dose became infected with Omicron, versus 20% of those with only three doses, demonstrating increased protection against infection. Infections were either asymptomatic or mild and no severe outcomes were seen. [4]
Note that this data is current up to August 5, 2022 and will be updated periodically as new information emerges.
References
Higdon, MM, et al. 2022. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. The Lancet Infectious Diseases. Published online June 22, 2022. Accessed at: https://doi.org/10.1016/S1473-3099(22)00409-1
Cohen MJ et al. 2022. Association of receiving a fourth dose of the BNT162b Vaccine with SARS-CoV-2 infection among health care workers in Israel. JAMA Netw Open. 5(8):e2224657. Published online August 2, 2022. Accessed at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794864
Table 2. Summary of open COVID-19 outbreaks in Alberta.
Facility Type
Calgary
Central
Edmonton
North
South
Total
Supportive Living/Home Living Sites
12
2
6
3
2
25
Long Term Care Facility
11
0
4
1
0
16
Acute Care Facility
0
0
7
0
0
7
Other
2
0
1
0
0
3
Total
25
2
18
4
2
51
Figure 3: Number of outbreaks by week opened.
Severe Outcomes
Table 3. Total Hospitalizations, ICU admissions and deaths (ever) among COVID-19 cases in Alberta by age group
Age Group
Cases
Hospitalized
ICU
Deaths
Count
Count
Case rate
Pop. rate
Count
Case rate
Pop. rate
Count
Case rate
Pop. rate
Total
632177
35301
5.6
799.3
4772
0.8
108.0
5720
0.9
129.5
Under 1 year
5478
627
11.4
1242.1
96
1.8
190.2
1
0.0
2.0
1-4 years
21950
520
2.4
239.5
55
0.3
25.3
1
0.0
0.5
5-9 years
31856
250
0.8
90.1
34
0.1
12.3
2
0.0
0.7
10-19 years
69791
609
0.9
114.3
77
0.1
14.5
2
0.0
0.4
20-29 years
104009
1714
1.6
290.2
182
0.2
30.8
25
0.0
4.2
30-39 years
119332
2814
2.4
393.8
352
0.3
49.3
52
0.0
7.3
40-49 years
99382
2993
3.0
492.4
590
0.6
97.1
121
0.1
19.9
50-59 years
72403
4320
6.0
784.6
978
1.4
177.6
317
0.4
57.6
60-69 years
46007
5857
12.7
1235.7
1246
2.7
262.9
754
1.6
159.1
70-79 years
26095
6658
25.5
2553.4
882
3.4
338.3
1332
5.1
510.8
80+ years
35872
8939
24.9
6349.9
280
0.8
198.9
3113
8.7
2211.4
Unknown
2
0
0.0
NA
0
0.0
NA
0
0.0
NA
Note:
Based on total hospitalizations and ICU admissions ever.
Row percent is out of the number of cases in each age group.
Each ICU admission is also included in the total number of hospitalization
Case rate (per 100 cases)
Population rate (per 100,000 population)
Figure 4: Number of COVID-19 cases currently in hospital (ICU and non-ICU) with a primary or contributing cause due to COVID-19. Please note, information on reason for hospitalization was unavailable prior to 2022-02-01 and is delayed by approximately one week from a hospitalization event.
Figure 5: Number of current COVID-19 cases in hospital (ICU and non-ICU)
Figure 6: Rate of new hospitalizations related to COVID-19 (7-day rolling average, average of current day and previous 6 days) by admission date in Alberta and by zone. Please note, information on reason for hospitalization was unavailable prior to 2022-02-01 and is delayed by approximately one week from a hospitalization event.
Figure 7: Rate of new hospitalizations (7-day rolling average, average of current day and previous 6 days) by admission date in Alberta and by zone
Figure 8: Daily COVID-19 attributed deaths. Data are subject to change; when death date is unavailable the date reported to Alberta Health is used until a death date is known.
Geospatial
Figure 9: Cumulative COVID-19 cases in Alberta by zone and date reported to Alberta Health. Cases without a postal code or incorrect postal codes are labelled as unknown.
Geography presented by Alberta Health Services Zones. Cases without a postal code or incorrect postal codes are not included. Standard scores are calculated to compare the 7-day case rate of each Zone to the provincial average. Scores are separated into 3 categories, with -1 to 1 being close to the provincial average, >1 being higher than average, and < -1 being lower than the provincial average.
Laboratory Testing
Figure 10: Tests performed for COVID-19 in Alberta by day. Tests can be performed for the same person multiple times.
Figure 11: Cumulative and daily test positivity rate for COVID-19 in Alberta.
Figure 12: Positivity rate for COVID-19 in Alberta by zone.
Variants
Summary
NOTE: People are identified as COVID-19 cases prior to variant of concern identification. As such, variant of concern reporting is delayed compared to date the case was reported to Alberta Health.
Due to the large number of positive COVID-19 cases, the lab screened a sample of positive cases between May 1, 2021 and May 31, 2021, September 9, 2021 and November 23, 2021, and December 23rd, 2021 and February 9, 2022.
As of February 2, 2023 the laboratory transitioned from variant screening to whole genome sequencing (WGS) only.
Figure 13: Proportion of whole genome sequenced variants by type (10 weeks). Note: the ‘minor lineages’ category combines all variants with <5% frequency that week; data not reported for previous 2 weeks due to reporting delays.
Note: As of February 2, 2023 the laboratory transitioned from variant screening to whole genome sequencing (WGS) only.
Figure 14: Variant of concern COVID-19 cases in Alberta by day. Note: cases are identified as COVID-19 positive prior to being identified as a variant of concern; data not reported for previous 2 weeks due to reporting delays.
Note: Genotype classification is based on the most specific typing available at time of reporting, either sequencing or screening results.
Figure 15: Percent of screened cases (confirmed) by variant of concern. Values are averaged over a 7 day period. Note: cases are identified as COVID-19 positive prior to being identified as a variant of concern. Data included up to end of day February 01, 2023.
Note: Genotype classification is based on the most specific typing available at time of reporting, either sequencing or screening results.
Wastewater surveillance
Project Details
The Alberta Wastewater Surveillance Program is a collaboration between the University of Calgary, University of Alberta, Alberta Precision Labs, and Alberta Health. SARS-CoV-2 virus has been demonstrated to be passed in the feces of a significant proportion of infected individuals, individuals infected with COVID-19 may pass the virus in their feces before they become asymptomatic. As such wastewater can provide an early indication of infection trends in a community. Wastewater monitoring is one of many tools in understanding the overall burden of infection in a community, and provides a broad picture of infection in a community.
More details on this project and additional wastewater data can be viewed on the University of Calgary’s Centre for Health Informatics’ COVID-19 wastewater dashboard
Click on your community’s Zone below to view its’ wastewater data
Figure 16: Average quantity of SARS CoV-2 virus (viral copies/mL) over time.
Wastewater Data is updated with the most current data delivered to Alberta Health. This data is received around the same time data is updated on the University of Calgary’s CHI Health tracker Monday, Wednesday, and Friday afternoons. These data are incorporated into Alberta Health wastewater reporting on the next scheduled reporting date. As such, there may be short and temporary discrepancies between the wastewater data displayed between the two websites. For more information on wastewater data interpretation, see the Data Notes tab.
Data Export
Data are subject to change. Fluctuations are expected as cases are investigated and updated. Data are provided for export in csv format.
The Provincial Surveillance Information system (PSI) is a laboratory surveillance system which receives positive results for all Notifiable Diseases and diseases under laboratory surveillance from Alberta Precision Labs (APL). The system also receives negative results for a subset of organisms such as COVID-19. The system contains basic information on characteristics and demographics such as age, zone and gender. The Communicable Disease Reporting System (CDRS) at Alberta Health and the Communicable Disease Outbreak Management (CDOM) system at Alberta Health Services contains information on COVID-19 cases. Data Integration and Measurement Reporting (DIMR) database at Alberta Health Services contains up to date information on people admitted and discharged from hospital in Alberta. Information such as hospitalizations and ICU admissions are received through enhanced case report forms sent by Alberta Health Services (AHS).
COVID-19 vaccinations and AEFIs are reported to the Provincial Immunization and Adverse Reaction to Immunization (Imm/ARI) repository. In Alberta, all health practitioners are required by law to report Adverse Events Following Immunization (AEFI) to Imm/ARI. The reporting requirements are outlined in the Immunization Regulation, under the Public Health Act. Case definitions are further defined in the AEFI Policy. As of January 1, 2021, all health practitioners are required to report all (both provincially funded and privately purchased) vaccinations electronically to Imm/ARI.
Wastewater surveillance data
Due to differences in Wastewater composition across the province, data should not be compared between municipalities. Instead, good practice when analyzing wastewater data is to look at the general trend within a community. Two SARS CoV-2 gene targets, the N1 and N2 genes, are tested for in the wastewater. The average signal in gene copies/mL is presented.
Definitions
COVID-19 Deaths
A death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death identified (e.g., trauma, poisoning, drug overdose).
A Medical Officer of Health or relevant public health authority may use their discretion when determining if a death was due to COVID-19, and their judgement will supersede the above criteria.
A death due to COVID-19 may be attributed when COVID-19 is the cause of death or is a contributing factor.
Lab Positivity
COVID-19 percent positivity in Alberta is calculated using the Test Over Test method, which is the same method employed by the US Centers for Disease Control and Prevention. The calculation is as follows:
Daily Number of Positive Tests / (Daily Number of Positive Tests + Daily Number of Negative Tests)
Q/RT-PCR tests are the only COVID-19 tests included in this calculation.
Pre-existing Conditions
The following pre-existing conditions are included in respective analyses: diabetes, hypertension, COPD, cancer, dementia, stroke, liver cirrhosis, cardiovascular diseases (including IHD and congestive heart failure), chronic kidney disease, and immuno-deficiency diseases.
Vaccine coverage
Individuals who received at least one dose was calculated as (# of individuals who received at least one dose) / (population estimate). Those who received two doses was calculated as (# of individuals who received two doses) / (population estimate).
As of January 19, 2022 all doses administered in First Nations communities are submitted directly into Imm/ARI and the data reconciliation resulted in the removal of approximately 20,000 doses.
Outbreaks
Reporting for outbreaks vary by site/location and time, please visit here for more details on the latest definitions.
Disclaimer
The content and format of this report are subject to change. Cases are under investigation and numbers may fluctuate as cases are resolved. Data included in the interactive data application are up-to-date as of end of day May 01, 2023.
10,050,276 total doses administered
91.1% 12+ population with 1 dose
87.7% 12+ population with 2 doses
Vaccination data are up-to-date as of end of day May 01, 2023
10,050,276 doses of COVID-19 vaccine have been administered in Alberta
91.1 percent of 12+ population with 1 dose (82.7% total population)
87.7 percent of 12+ population with 2 doses (78.4% total population)
Number of COVID-19 vaccine doses administered by dose and day**
Table 1. Breakdown of COVID-19 vaccine doses administered by provider.
Dose 1
Dose 2
Dose 3
Dose 4
Total administered
Alberta Health Services
1,929,602
1,675,813
439,037
135,566
4,180,018
Pharmacies
1,602,346
1,671,081
1,344,160
959,742
5,577,329
Other
120,018
107,158
43,863
21,890
292,929
Total
3,651,966
3,454,052
1,827,060
1,117,198
10,050,276
Note: Other includes submissions from First Nations communities and online submissions from other providers (e.g. physician clinics).
Cumulative percent of individuals who received one dose, two doses and three doses by day in Alberta
Table 2. Summary of COVID-19 vaccine doses administered and vaccine coverage by age group
Age group
Population
1 dose
% of population with 1 dose
2 doses
% of population with 2 doses
3 doses
% of population with 3 doses
4 doses
Total administered
6m-11m
25,704
919
3.6
264
1.0
0
0.0
0
1,285
01-04
217,106
20,987
9.7
11,823
5.4
13
0.0
0
33,796
05-11
391,068
204,906
52.4
154,770
39.6
19,722
5.0
74
379,472
12-14
162,409
144,691
89.1
140,869
86.7
28,719
17.7
4,997
319,271
15-19
256,523
225,677
88.0
215,312
83.9
63,539
24.8
14,117
518,396
20-24
276,617
241,911
87.5
227,622
82.3
78,273
28.3
18,734
565,904
25-29
313,935
264,978
84.4
250,354
79.7
91,956
29.3
25,596
632,024
30-34
355,845
303,932
85.4
289,964
81.5
118,015
33.2
39,645
750,374
35-39
358,781
316,189
88.1
304,773
84.9
137,140
38.2
49,072
805,915
40-44
319,435
286,701
89.8
279,411
87.5
140,811
44.1
51,338
757,133
45-49
288,414
259,236
89.9
252,518
87.6
138,808
48.1
55,096
704,730
50-54
266,416
244,407
91.7
238,331
89.5
145,591
54.6
67,209
694,772
55-59
284,174
257,174
90.5
248,902
87.6
165,054
58.1
89,701
760,199
60-64
264,112
251,168
95.1
244,265
92.5
181,339
68.7
127,818
804,137
65-69
209,854
206,290
98.3
202,381
96.4
168,391
80.2
145,773
722,560
70-74
157,684
155,907
98.9
155,301
98.5
133,945
84.9
148,920
593,916
75-79
103,069
99,470
96.5
98,317
95.4
91,633
88.9
118,535
407,860
80-84
68,592
65,254
95.1
64,488
94.0
59,107
86.2
76,951
265,783
85-89
44,279
41,444
93.6
40,944
92.5
37,431
84.5
49,084
168,889
90+
27,903
26,206
93.9
25,915
92.9
24,430
87.6
34,417
110,963
Unknown
0
32,246
0.0
14,283
0.0
2,987
0.0
132
49,645
18+
3,442,298
3,144,760
91.4
3,025,219
87.9
1,748,480
50.8
1,105,008
9,014,814
12+
3,758,041
3,422,881
91.1
3,293,950
87.7
1,807,169
48.1
1,117,135
9,632,471
5+
4,149,109
3,627,787
87.4
3,448,720
83.1
1,826,891
44.0
1,117,209
10,011,943
ALL
4,416,692
3,651,966
82.7
3,461,734
78.4
1,826,904
41.4
1,117,209
10,050,276
Note 1: individuals who received a first dose in one age category may cross into another age category for a second or third dose.
Note 2: The age group 5-11 year olds includes those who received the Pfizer-BioNTech Comirnaty pediatric COVID-19 vaccine and those who were eligible to receive the Pfizer-BioNTech Comirnaty COVID-19 vaccine because they were 11 but would turn 12 in 2021.
Vaccine coverage by day, dose and age group in Alberta
Vaccine coverage rate by local geographic area**
Geographies can be displayed by Alberta local geographic area (LGA). Individuals without a postal code or incorrect postal codes are not included. The colour categories for each LGA are based on the percent of the population (all ages) vaccinated. Vaccine uptake rates for the Vermilion River County LGA are underestimated as the Saskatchewan Health Authority provides public health services to all residents of Lloydminster.
2,869 adverse events following immunization (AEFI) have been reported to Alberta Health. This represents 2,760 people, and 3,002 symptoms.
Number of adverse events following immunization (AEFI) by condition reported in Alberta
Note: Information is collected on individuals and reported to Alberta Health when an AEFI is confirmed. One AEFI report can have multiple events associated with it.
Table 3. Number of adverse events following immunization (AEFI) by age group reported in Alberta
Age group
AEFIs (n)
Percent of doses administered (%)
Rate (per 100,000 doses administered)
Total doses administered
6m-11m
1
0.078
77.8
1,285
01-04
9
0.027
26.6
33,796
05-11
54
0.014
14.2
379,472
12-14
62
0.019
19.4
319,271
15-19
125
0.024
24.1
518,396
20-24
157
0.028
27.7
565,904
25-29
183
0.029
29.0
632,024
30-34
288
0.038
38.4
750,374
35-39
269
0.033
33.4
805,915
40-44
337
0.045
44.5
757,133
45-49
268
0.038
38.0
704,730
50-54
236
0.034
34.0
694,772
55-59
248
0.033
32.6
760,199
60-64
227
0.028
28.2
804,137
65-69
137
0.019
19.0
722,560
70-74
122
0.021
20.5
593,916
75-79
64
0.016
15.7
407,860
80-84
30
0.011
11.3
265,783
85-89
30
0.018
17.8
168,889
90+
16
0.014
14.4
110,963
Unknown
6
0.000
0.0
0
All
2,869
0.029
28.5
10,050,276
Note: The age group 5-11 year olds includes those who received the Pfizer-BioNTech Comirnaty pediatric COVID-19 vaccine and those who were eligible to receive the Pfizer-BioNTech Comirnaty COVID-19 vaccine because they were 11 but would turn 12 in 2021.
Table 4. Number of adverse events following immunization (AEFI) by vaccine name reported in Alberta
Vaccine name
AEFIs (n)
Rate (per 100,000 doses)
Doses
AstraZeneca
219
69.5
315,067
Janssen
7
79.7
8,780
Moderna
754
36.2
2,082,070
Novavax
5
161.7
3,093
Pfizer/BioNTech
1,887
24.8
7,595,951
All
2,872
28.6
10,050,276
Note: One AEFI report can be temporally associated with multiple vaccines on the same immunization date and multiple adverse event types. One AEFI report also can be temporally associated with same vaccine on different immunization date.